Vanguard Group
OVID icon

Vanguard Group’s Ovid Therapeutics OVID Stock Holding History

Vanguard Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.01M Buy
3,072,227
+251,414
+9% +$387K ﹤0.01% 3253
2025
Q3 		$3.67M Buy
2,820,813
+184,698
+7% +$160K ﹤0.01% 3377
2025
Q2 		$870K Sell
2,636,115
-472,666
-15% -$142K ﹤0.01% 3776
2025
Q1 		$970K Sell
3,108,781
-39,301
-1% -$24.2K ﹤0.01% 3719
2024
Q4 		$2.94M Buy
3,148,082
+5,643
+0.2% +$6.32K ﹤0.01% 3447
2024
Q3 		$3.71M Buy
3,142,439
+53,046
+2% +$55.4K ﹤0.01% 3380
2024
Q2 		$2.38M Buy
3,089,393
+113,085
+4% +$315K ﹤0.01% 3502
2024
Q1 		$9.08M Sell
2,976,308
-13,469
-0.5% -$45.1K ﹤0.01% 3015
2023
Q4 		$9.63M Buy
2,989,777
+23,360
+0.8% +$79.9K ﹤0.01% 2970
2023
Q3 		$11.4M Buy
2,966,417
+67,189
+2% +$242K ﹤0.01% 2818
2023
Q2 		$9.51M Buy
2,899,228
+288,626
+11% +$980K ﹤0.01% 2976
2023
Q1 		$6.74M Buy
2,610,602
+28,866
+1% +$68.4K ﹤0.01% 3165
2022
Q4 		$4.8M Buy
2,581,736
+1,146
+0% +$1.95K ﹤0.01% 3329
2022
Q3 		$4.75M Buy
2,580,590
+45,500
+2% +$95.2K ﹤0.01% 3358
2022
Q2 		$5.45M Sell
2,535,090
-1,152,819
-31% -$2.79M ﹤0.01% 3339
2022
Q1 		$11.6M Buy
3,687,909
+245,291
+7% +$772K ﹤0.01% 3073
2021
Q4 		$11.1M Buy
3,442,618
+60,537
+2% +$207K ﹤0.01% 3154
2021
Q3 		$11.4M Sell
3,382,081
-123,556
-4% -$451K ﹤0.01% 3164
2021
Q2 		$13.7M Buy
3,505,637
+9,251
+0.3% +$36.5K ﹤0.01% 3044
2021
Q1 		$14.1M Buy
3,496,386
+390,634
+13% +$1.3M ﹤0.01% 2967
2020
Q4 		$7.17M Buy
3,105,752
+509,417
+20% +$2.37M ﹤0.01% 3164
2020
Q3 		$14.9M Buy
2,596,335
+474,703
+22% +$3.18M ﹤0.01% 2591
2020
Q2 		$15.6M Buy
2,121,632
+422,661
+25% +$1.98M ﹤0.01% 2547
2020
Q1 		$5.06M Buy
1,698,971
+210,442
+14% +$709K ﹤0.01% 2969
2019
Q4 		$6.18M Buy
1,488,529
+423,961
+40% +$1.34M ﹤0.01% 3094
2019
Q3 		$3.45M Sell
1,064,568
-33,046
-3% -$75.1K ﹤0.01% 3270
2019
Q2 		$2.03M Buy
1,097,614
+443,490
+68% +$792K ﹤0.01% 3473
2019
Q1 		$1.16M Buy
654,124
+361,864
+124% +$905K ﹤0.01% 3585
2018
Q4 		$708K Sell
292,260
-154,510
-35% -$705K ﹤0.01% 3659
2018
Q3 		$2.53M Buy
446,770
+2,003
+0.5% +$15.2K ﹤0.01% 3452
2018
Q2 		$3.47M Buy
444,767
+44,237
+11% +$380K ﹤0.01% 3336
2018
Q1 		$2.83M Buy
400,530
+66,464
+20% +$538K ﹤0.01% 3345
2017
Q4 		$3.3M Buy
334,066
+172,409
+107% +$1.58M ﹤0.01% 3274
2017
Q3 		$1.39M Buy
161,657
+62,340
+63% +$519K ﹤0.01% 3500
2017
Q2 		$1.04M Buy
+99,317
New +$1.3M ﹤0.01% 3558

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's OVID Position: Q4 2025 in Review

Vanguard Group increased its Ovid Therapeutics (OVID) stake by 8.9% in Q4 2025, buying an estimated $387K and bringing the position to 3,072,227 shares worth $5.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3253.

Vanguard Group first reported a position in OVID in Q2 2017 and has held it in 35 quarters since. The position peaked at $15.6M in Q2 2020. 84 funds tracked by Wall St. Rank hold OVID as of Q4 2025.

  • Vanguard Group held 3,072,227 shares of Ovid Therapeutics worth $5.01M as of Q4 2025.
  • Vanguard Group bought 251,414 Ovid Therapeutics shares in Q4 2025, an estimated $387K.
  • Ovid Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3253 holding.
  • Vanguard Group first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 35 quarters since.
  • Vanguard Group's Ovid Therapeutics position peaked at $15.6M in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.